William Blair Downgrades Cardiff Oncology to Market Perform
William Blair analyst Andy Hsieh downgrades Cardiff Oncology (NASDAQ:CRDF) from Outperform to Market Perform.
Share
Why It Matters
An expert who studies companies just said Cardiff Oncology is less exciting than before. When experts change their minds like this, it's worth noticing what they saw that worried them.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.